Clinical trials: NAT2 Genotype
NAT2 Genotype
Isoniazid Dosage Prediction Model Development
Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment. However, treatment with INH is complicated by polymorphisms in the expression of the enzyme system primarily responsible for its…
- Trial name
- NCT02747654
- Testing
- genotype
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center